• 1
    Farmer PB. Exposure biomarkers for the study of toxicological impact on carcinogenic processes. IARC Sci Publ 2004; 157: 7190.
  • 2
    Braithwaite E, Wu X, Wang Z. Repair of DNA lesions: mechanisms and relative repair efficiencies. Mutat Res 1999; 424: 20719.
  • 3
    Doherty KM, Sharma S, Uzdilla L, Wilson TM, Cui S, Vindigni A, Brosh RM,Jr. RECQ1 helicase interacts with human mismatch repair factors that regulate genetic recombination. J Biol Chem 2005; 280: 2808594.
  • 4
    Elliott B, Jasin M. Repair of double-strand breaks by homologous recombination in mismatch repair-defective mammalian cells. Mol Cell Biol 2001; 21: 267182.
  • 5
    Mu D, Tursun M, Duckett DR, Drummond JT, Modrich P, Sancar A. Recognition and repair of compound DNA lesions (base damage and mismatch) by human mismatch repair and excision repair systems. Mol Cell Biol 1997; 17: 7609.
  • 6
    Stojic L, Brun R, Jiricny J. Mismatch repair and DNA damage signalling. DNA Repair (Amst) 2004; 3: 1091101.
  • 7
    Branch P, Hampson R, Karran P. DNA mismatch binding defects, DNA damage tolerance, and mutator phenotypes in human colorectal carcinoma cell lines. Cancer Res 1995; 55: 23049.
  • 8
    Papouli E, Cejka P, Jiricny J. Dependence of the cytotoxicity of DNA-damaging agents on the mismatch repair status of human cells. Cancer Res 2004; 64: 33914.
  • 9
    Claij N, te Riele H. Msh2 deficiency does not contribute to cisplatin resistance in mouse embryonic stem cells. Oncogene 2004; 23: 2604.
  • 10
    Duckett DR, Drummond JT, Murchie AI, Reardon JT, Sancar A, Lilley DM, Modrich P. Human MutSalpha recognizes damaged DNA base pairs containing O6-methylguanine, O4-methylthymine, or the cisplatin-d(GpG) adduct. Proc Natl Acad Sci USA 1996; 93: 64437.
  • 11
    Fourrier L, Brooks P, Malinge JM. Binding discrimination of MutS to a set of lesions and compound lesions (base damage and mismatch) reveals its potential role as a cisplatin-damaged DNA sensing protein. J Biol Chem 2003; 278: 2126775.
  • 12
    Li GM, Wang H, Romano LJ. Human MutSα specifically binds to DNA containing aminofluorene and acetylaminofluorene adducts. J Biol Chem 1996; 271: 240848.
  • 13
    Mazurek A, Berardini M, Fishel R. Activation of human MutS homologs by 8-oxo-guanine DNA damage. J Biol Chem 2002; 277: 82606.
  • 14
    Wang H, Lawrence CW, Li GM, Hays JB. Specific binding of human MSH2.MSH6 mismatch-repair protein heterodimers to DNA incorporating thymine- or uracil-containing UV light photoproducts opposite mismatched bases. J Biol Chem 1999; 274: 16894900.
  • 15
    Wu J, Gu L, Wang H, Geacintov NE, Li GM. Mismatch repair processing of carcinogen-DNA adducts triggers apoptosis. Mol Cell Biol 1999; 19: 8292301.
  • 16
    Wu J, Zhu BB, Yu J, Zhu H, Qiu L, Kindy MS, Gu L, Seidel A, Li GM. In vitro and in vivo modulations of benzo[c]phenanthrene-DNA adducts by DNA mismatch repair system. Nucleic Acids Res 2003; 31: 642834.
  • 17
    Bertrand P, Tishkoff DX, Filosi N, Dasgupta R, Kolodner RD. Physical interaction between components of DNA mismatch repair and nucleotide excision repair. Proc Natl Acad Sci USA 1998; 95: 1427883.
  • 18
    Lan L, Hayashi T, Rabeya RM, Nakajima S, Kanno S, Takao M, Matsunaga T, Yoshino M, Ichikawa M, te Riele H, Tsuchiya S, Tanaka K, et al. Functional and physical interactions between ERCC1 and MSH2 complexes for resistance to cis-diamminedichloroplatinum(II) in mammalian cells. DNA Repair (Amst) 2004; 3: 13543.
  • 19
    Fang Y, Tsao CC, Goodman BK, Furumai R, Tirado CA, Abraham RT, Wang XF. ATR functions as a gene dosage-dependent tumor suppressor on a mismatch repair-deficient background. EMBO J 2004; 23: 316474.
  • 20
    de Wind N, Dekker M, Berns A, Radman M, te Riele H. Inactivation of the mouse Msh2 gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination, and predisposition to cancer. Cell 1995; 82: 32130.
  • 21
    Phillips DH, Hewer A, Arlt VM. 32P-postlabeling analysis of DNA adducts. Methods Mol Biol 2005; 291: 312.
  • 22
    Hanawalt PC, Ford JM, Lloyd DR. Functional characterization of global genomic DNA repair and its implications for cancer. Mutat Res 2003; 544: 10714.
  • 23
    Colussi C, Fiumicino S, Giuliani A, Rosini S, Musiani P, Macri C, Potten CS, Crescenzi M, Bignami M. 1,2-Dimethylhydrazine-induced colon carcinoma and lymphoma in msh2(−/−) mice. J Natl Cancer Inst 2001; 93: 153440.
  • 24
    de Wind N, Dekker M, Claij N, Jansen L, van Klink Y, Radman M, Riggins G, van der Valk M, van't Wout K, te Riele H. HNPC. C-like cancer predisposition in mice through simultaneous loss of Msh3 and Msh6 mismatch-repair protein functions. Nat Genet 1999; 23: 35962.
  • 25
    Strate LL, Syngal S. Hereditary colorectal cancer syndromes. Cancer Causes Control 2005; 16: 20113.
  • 26
    Bougeard G, Charbonnier F, Moerman A, Martin C, Ruchoux MM, Drouot N, Frebourg T. Early onset brain tumor and lymphoma in MSH2-deficient children. Am J Hum Genet 2003; 72: 2136.
  • 27
    De Vos M, Hayward BE, Picton S, Sheridan E, Bonthron DT. Novel. PMS2 pseudogenes can conceal recessive mutations causing a distinctive childhood cancer syndrome. Am J Hum Genet 2004; 74: 9544.
  • 28
    Whiteside D, McLeod R, Graham G, Steckley JL, Booth K, Somerville MJ, Andrew SE. A homozygous germ-line mutation in the human MSH2 gene predisposes to hematological malignancy and multiple cafe-au-lait spots. Cancer Res 2002; 62: 35962.
  • 29
    Campbell MR, Nation PN, Andrew SE. A lack of DNA mismatch repair on an athymic murine background predisposes to hematologic malignancy. Cancer Res 2005; 65: 262635.
  • 30
    Reitmair AH, Schmits R, Ewel A, Bapat B, Redston M, Mitri A, Waterhouse P, Mittrucker HW, Wakeham A, Liu B. MSH2 deficient mice are viable and susceptible to lymphoid tumours. Nat Genet 1995; 11: 6470.
  • 31
    Claij N, van der Wal A, Dekker M, Jansen L, te Riele H. DNA mismatch repair deficiency stimulates N-ethyl-N-nitrosourea-induced mutagenesis and lymphomagenesis. Cancer Res 2003; 63: 20626.
  • 32
    Meira LB, Cheo DL, Reis AM, Claij N, Burns DK, te Riele H, Friedberg EC. Mice defective in the mismatch repair gene Msh2 show increased predisposition to UVB radiation-induced skin cancer. DNA Repair (Amst) 2002; 1: 92934.
  • 33
    Andrew SE, McKinnon M, Cheng BS, Francis A, Penney J, Reitmair AH, Mak TW, Jirik FR. Tissues of MSH2-deficient mice demonstrate hypermutability on exposure to a DNA methylating agent. Proc Natl Acad Sci USA 1998; 95: 112630.
  • 34
    Toft NJ, Winton DJ, Kelly J, Howard LA, Dekker M, te Riele H, Arends MJ, Wyllie AH, Margison GP, Clarke AR. Msh2 status modulates both apoptosis and mutation frequency in the murine small intestine. Proc Natl Acad Sci USA 1999; 96: 39114.
  • 35
    Kunkel TA, Erie DA. DNA Mismatch Repair. Annu Rev Biochem 2004; 74: 681710.
  • 36
    Bellacosa A. Functional interactions and signaling properties of mammalian DNA mismatch repair proteins. Cell Death Differ 2001; 8: 107692.
  • 37
    Shimodaira H, Yoshioka-Yamashita A, Kolodner RD, Wang JY. Interaction of mismatch repair protein PMS2 and the p53-related transcription factor p73 in apoptosis response to cisplatin. Proc Natl Acad Sci USA 2003; 100: 24205.
  • 38
    Young LC, Thulien KJ, Campbell MR, Tron VA, Andrew SE. DNA mismatch repair proteins promote apoptosis and suppress tumorigenesis in response to UVB irradiation: an in vivo study. Carcinogenesis 2004; 25: 18217.
  • 39
    Hickman MJ, Samson LD. Role of DNA mismatch repair and p53 in signaling induction of apoptosis by alkylating agents. Proc Natl Acad Sci USA 1999; 96: 107649.
  • 40
    Bernstein C, Bernstein H, Payne CM, Garewal H. DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis. Mutat Res 2002; 511: 14578.
  • 41
    Claij N, te Riele H. Methylation tolerance in mismatch repair proficient cells with low MSH2 protein level. Oncogene 2002; 21: 28739.
  • 42
    de Wind N, Dekker M, van Rossum A, van der Valk M, te Riele H. Mouse models for hereditary nonpolyposis colorectal cancer. Cancer Res 1998; 58: 24855.